You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 265 No. 12, March 27, 1991 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Letters
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The FDA and Drug Marketing Expenditures

Herbert L. Joseph, MD
Vallejo, Calif

JAMA. 1991;265(12):1528.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

An article in the November 14, 1990, issue of JAMA, "The Federal Regulation of Prescription Drug Advertising and Promotion,"1 was most informative. There was, however, conspicuous failure to address a key question: does the Food and Drug Administration (FDA) consider how much advertising and promotion add to the escalating cost of drugs? An answer to this question is particularly appropriate at this time when there is a public mandate for legislation to control the high cost of medical care. . . . [Full Text PDF of this Article]



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.